Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck KGaA
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
MTI’s Top 21 Of ’21: Omicron, Remote Reg Assessments, QSR Delays, US Capitol Insurrection Make Headlines
What a doozy of a year 2021 was in the medical device space – capped on one end by a deadly insurrection blasted by medtech heavy-hitters, and on the other end by news that the COVID-19 Omicron variant is wreaking havoc on some diagnostics (and many US FDA on-site inspections). Here are Medtech Insight’s Top 21 US regulation, policy, quality control and compliance stories of 2021, as determined by reader interest.
- Research, Analytical Equipment & Supplies
- Drug Delivery
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Acadiana Ventures Inc.
- Allergopharma Joachim Ganzer KG
- AmpTec GmbH
- EMD Pharmaceuticals
- Grzybowski Scientific Inventions (GSI)
- Intermolecular Inc
- JRH Biosciences
- Merck Hoei Ltd.
- Ormet Circuts Inc.
- EMD Serono, Inc.
- Versum Materials, Inc.